[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc purchased 856,760 ordinary shares of £0.01 each for cancellation under the second tranche of its share buyback programme announced 31 July 2025. The purchases were executed on 08 August 2025 on the London Stock Exchange at prices between 353.5000p and 356.1000p, with a volume-weighted average price of 354.6173p.

Following settlement the company's registered share capital is 8,979,735,788 ordinary shares, of which 3,880,205 are held as treasury shares, leaving 8,975,855,583 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided RNS link and on Haleon's investor website.

Insights

Financial Analyst

TL;DR: Small executed tranche of announced buyback; immaterial to outstanding share count and per-share metrics at company scale.

The transaction shows active execution of the second tranche of the company’s buyback programme, with 856,760 shares bought at a VWAP of 354.6173p. Relative to the registered share capital of 8.98 billion shares, this tranche represents a de minimis reduction in share count and is unlikely to meaningfully affect EPS or ownership thresholds. The announcement and RNS trade breakdown provide transparency on execution; investors should treat this as routine return-of-capital activity rather than a material capital-structure change.

Corporate Governance Expert

TL;DR: Execution of the buyback tranche demonstrates governance follow-through; the scale of purchases is negligible versus total shares.

The filing documents compliance with disclosure rules and supplies post-settlement share counts and treasury holdings. Reporting the highest, lowest and VWAP prices and publishing a full trade breakdown follows market best practice. Given the tiny percentage reduction in outstanding shares, this tranche does not materially alter shareholder voting dynamics or regulatory notification thresholds, though it reflects management's ongoing capital allocation choices under the announced programme.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	11 August 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

11 August 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 856,760 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	08 August 2025	08 August 2025	08 August 2025
Number of Shares purchased:	856,760	-	-
Highest price paid per Share (p):	356.1000	-	-
Lowest price paid per Share (p):	353.5000	-	-
Volume weighted average price paid per Share (p):	354.6173	-	-

Following the settlement of the above, the Company's registered share capital is 8,979,735,788 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,975,855,583 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/6867U_1-2025-8-8.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: August 11, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What did Haleon (HLN) announce in this Form 6-K?

Haleon purchased 856,760 ordinary shares on 08 August 2025 under the second tranche of its buyback programme; VWAP 354.6173p; high 356.1000p; low 353.5000p.

How many shares does Haleon have after the purchase (HLN)?

Registered share capital: 8,979,735,788 ordinary shares; 3,880,205 held as treasury; 8,975,855,583 ordinary shares carry voting rights.

On which venue were the shares purchased?

The shares listed in this announcement were purchased on the London Stock Exchange on 08 August 2025; no purchases were recorded on CBOE (UK)/BXE or CBOE (UK)/CXE for this tranche.

Is a detailed breakdown of the individual trades available?

Yes. A full breakdown is available via the RNS PDF link provided in the announcement and on Haleon's investor website.

Does this announcement constitute an offer for securities?

No. The announcement explicitly states it does not constitute, or form part of, an offer or solicitation of an offer for securities in any jurisdiction.